|
|
Blood, 15 January 2004, Vol. 103, No. 2, pp. 656-663.
Prepublished online as a Blood First Edition Paper on October 16, 2003; DOI 10.1182/blood-2003-07-2559.
Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens
Roberto Bellucci,
Catherine J. Wu,
Sabina Chiaretti,
Edie Weller,
Faith E. Davies,
Edwin P. Alyea,
Glenn Dranoff,
Kenneth C. Anderson,
Nikhil C. Munshi, and
Jerome Ritz
From the Departments of Medical Oncology and Biostatistics, Dana-Farber Cancer Institute; the University of Leeds, West Yorkshire, United Kingdom; and the Department of Medicine, Brigham and Woman's Hospital, Harvard Medical School, Boston, MA.
The ability of donor lymphocyte infusions (DLIs) to induce complete responses (CRs) in patients with relapsed myeloma after allogeneic bone marrow transplantation (BMT) provides clear evidence of an effective graft-versus-myeloma (GVM) response. To identify target antigens of the GVM response, we screened a myeloma cDNA expression library with post-DLI serum from 4 patients with myeloma who achieved CR after DLI and 1 patient who was in CR before DLI. We identified a panel of 13 gene products reactive with post-DLI serum but negative with pre-DLI and pre-BMT serum. Antibodies to these proteins were not detected in the sera of 10 patients who underwent allogeneic BMT without DLI and 5 patients with acute graft-versus-host disease (GVHD). Minimal reactivity with these proteins was detected in the sera of 20 healthy donors and 20 patients with chronic GVHD. In contrast, 5 of these proteins were recognized by more than 1 myeloma DLI responder. Testing of serial serum samples showed an association between antibody response and time of best response after DLI. The expression of these genes was evaluated in primary myeloma cells and in normal plasma cells. This study demonstrates that the GVM response is associated with antibody responses to highly expressed myeloma-associated antigens.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Baskar, J. M. Suschak, I. Samija, R. Srinivasan, R. W. Childs, S. Z. Pavletic, M. R. Bishop, and C. Rader
A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display
Blood,
November 12, 2009;
114(20):
4494 - 4502.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Blotta, P. Tassone, R. H. Prabhala, P. Tagliaferri, D. Cervi, S. Amin, J. Jakubikova, Y.-T. Tai, K. Podar, C. S. Mitsiades, et al.
Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance
Blood,
October 8, 2009;
114(15):
3276 - 3284.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Pfistershammer, A. Lawitschka, C. Klauser, J. Leitner, R. Weigl, M. H. M. Heemskerk, W. F. Pickl, O. Majdic, G. A. Bohmig, G. F. Fischer, et al.
Allogeneic disparities in immunoglobulin-like transcript 5 induce potent antibody responses in hematopoietic stem cell transplant recipients
Blood,
September 10, 2009;
114(11):
2323 - 2332.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Bellucci, S. Oertelt, M. Gallagher, S. Li, E. Zorn, E. Weller, F. Porcheray, E. P. Alyea, R. J. Soiffer, N. C. Munshi, et al.
Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis
Blood,
March 1, 2007;
109(5):
2001 - 2007.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Lu, K. L. Knutson, E. Gad, and M. L. Disis
The Tumor Antigen Repertoire Identified in Tumor-Bearing Neu Transgenic Mice Predicts Human Tumor Antigens
Cancer Res.,
October 1, 2006;
66(19):
9754 - 9761.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Hideshima, D. Chauhan, P. Richardson, and K. C. Anderson
Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6345 - 6350.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Wu, M. Biernacki, J. L. Kutok, S. Rogers, L. Chen, X.-F. Yang, R. J. Soiffer, and J. Ritz
Graft-versus-Leukemia Target Antigens in Chronic Myelogenous Leukemia Are Expressed on Myeloid Progenitor Cells
Clin. Cancer Res.,
June 15, 2005;
11(12):
4504 - 4511.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Bellucci, E. P. Alyea, S. Chiaretti, C. J. Wu, E. Zorn, E. Weller, B. Wu, C. Canning, R. Schlossman, N. C. Munshi, et al.
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor
Blood,
May 15, 2005;
105(10):
3945 - 3950.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. M. Lokhorst, K. Wu, L. F. Verdonck, L. L. Laterveer, N. W. C. J. van de Donk, M. H. J. van Oers, J. J. Cornelissen, and A. V. Schattenberg
The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma
Blood,
June 1, 2004;
103(11):
4362 - 4364.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|